Northwell Health to Advance Health Care Innovation Amid COVID-19 Pandemic at Constellation Forum

Northwell Health will host its third annual Constellation Forum virtually on Thursday, August 6 from 11 a.m. to 2 p.m. This year’s Forum will focus on the coronavirus disease 2019 (COVID-19) pandemic as it has highlighted the increased demands on health care innovation and on those who bring it to life. All are welcome to register for the free event here.

The Constellation Forum will explore what can be learned from efforts today in order to prepare whatever comes next. Northwell’s President and CEO, Michael Dowling, and an influential group of leaders, including Eric Schmidt, Former CEO & Chairman of Google and Co-Founder of Schmidt Futures; Joaquin Duato, Vice Chairman of the Executive Committee from Johnson & Johnson; Kevin Lobo, Chief Executive Officer of Stryker; Ann Lamont, Co-Founder & Managing Partner at Oak HC/FT; Cori Bargmann, Head of Science at the Chan Zuckerberg Initiative; Stanley Bergman, Chairman of the Board & CEO of Henry Schein; Geoffrey Ling, Founding Director of DARPA Biological Technologies Office and Chief Executive Officer of On Demand Pharmaceuticals and, Kevin Tracey, President and CEO of the Feinstein Institutes for Medical Research will come together to share insights, best practices and the challenges facing health care amid this unprecedented time in order to collectively advance health care innovation.

To recognize Governor Andrew Cuomo for his leadership during this crisis, he will be presented with an honorary degree and provide remarks.

“Northwell Health has been at the center of the COVID-19 pandemic, treating more patients than any other health system globally and is working vigorously to overcome its challenges,” said Mr. Dowling. “This Forum gives us the chance to further enhance collaboration and accelerate changes within health care to benefit not only our patients but also patients around the world.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”